Utility of lncRNAs as predictive markers for immune checkpoint inhibitor therapy in renal cell carcinoma.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09399
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Yamaguchi University
• Principal Investigator: Hirata Hiroshi 山口大学, 大学院医学系研究科, 講師 (40781307)
• Co-Investigator(Kenkyū-buntansha): 早野 崇英 山口大学, 大学院医学系研究科, 講師 (30642392) ; 松山 豪泰 山口大学, 大学院医学系研究科, 教授(特命) (70209667)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 腎細胞がん / lncRNA

Outline of Final Research Achievements

In this study, the lncRNA LRRC75A-AS1, which was upregulated in RCC tissue from patients who failed ICI treatment, was identified by RNAsequencing with the aim of discovering an lncRNA that could predict the efficacy of ICI treatment in RCC. In basic experiments using human renal cell carcinoma cell lines, siRNA downregulation of the lncRNA LRRC75A-AS1 was associated with a higher risk of post-operative recurrence. The results showed a statistically significant reduction in the proliferative and invasive potential of kidney cancer cells when siRNA expression was reduced.

Free Research Field

腎がん

Academic Significance and Societal Importance of the Research Achievements

我々の結果は、今後腎がん治療に際の免疫チェックポイント阻害剤を使用する際に、前もって効果を判定できる新たなバイオマーカーとなる可能性がある。腎癌のみならず多種の癌のICI治療予測のマーカーとなる可能性もあり、広く学術的、科学技術的に、また社会全体に波及効果が期待できる。